|Ms. Grete Hogstad||VP of Strategic Marketing||1.43M||N/A||1956|
|Mr. Daniel Schneider||Pres & CEO||N/A||N/A||N/A|
|Mr. Erik Dahl||Chief Financial Officer||N/A||N/A||1957|
|Ms. Gry Stensrud||VP of Technical Devel. & Operations||N/A||N/A||1970|
|Mr. Espen Njåstad||Head of Nordic Cancer Commercial Operations||N/A||N/A||N/A|
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Visonac that has completed Phase II study for the treatment of moderate to severe acne; and Cevira, which has completed Phase II study for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.
Photocure ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.